Pros and cons of using aberrant glycosylation as companion biomarkers for therapeutics in cancer

키워드

참고문헌 (52)

1. Global health risks: mortality and burden of disease attributable to selected major risks, "World Health Organization Report", ~ (2009)
2. Ross, J. S, "Integrating diagnostics and therapeutics: revolutionizing drug discovery and patient care", Drug. Discov. Today, 70, pp.859~864 (2002)
3. Nowell, P, "A minute chromosome in human chronic granulocytic leukemia", Science, 132, pp.1497~
4. Lugo, T. G, "Tyrosine kinase activity and transformation potency of bcr-abl oncogene products", Science, 247, pp.1079~1082 (1990)
5. Druker, B. J, "Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells", Nat. Med, 2, pp.561~566 (1996)
6. Slamon, D. J, "Human breast cancer: correlation of relapse and survival with amplification of the HER-2", neu oncogene, 1987, pp.235, 177~182
7. Slamon, D. J, "Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2", N. Engl. J. Med, 344, pp.783~792 (2001)
8. Vogel, C. L, "Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer", J. Clin. Oncol, 20, pp.719~726 (2002)
9. Herbst. R. S, "Gefitinib-a novel targeted approach to treating cancer", Nat. Rev. Cancer, 41, pp.956~965 (2004)
10. Ferrara, N, "VEGF as a therapeutic target in cancer", Oncology, 69(suppl 3), pp.11~16 (2005)
11. Soda, M, "Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer", Nature, 448, pp.561~566 (2007)
12. Vo, T. T, "BH3-only proteins and their effects on cancer", Adv. Exp. Med. Biol, 687, pp.49~63 (2010)
13. Farmer, H, "Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy", Nature, 434, pp.917~921 (2005)
14. Masamura, S, "Estrogen deprivation causes estradiol hypersensitivity in human breast cancer cells", J. Clin. Endocrinol. Metab, 80, pp.2918~2925 (1995)
15. Baxter, E. J, "Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders", Lancet, 365, pp.1054~1061 (2005)
16. Liu, P, "Targeting the phosphoinositide 3-kinase pathway in cancer", Nat. Rev. Drug Discov, 8, pp.2 (2009), 627~644
17. Swaroop, A, "Unraveling a multifactorial late-onset disease: from genetic susceptibility to disease mechanisms for age-related macular degeneration", Annu. Rev. Genomics Hum. Genet, 10, pp.19~43 (2009)
18. Johnson, A. D, "An open access database of genome-wide association results", BMC Med. Genet, 10, pp.6~ (2009)
19. Reddy, E. P, "A point mutation is responsible for the acquisition of transforming properties of the T24 human bladder carcinoma oncogene", Nature, 300, pp.149~152 (1982)
20. Capon, D. J, "Activation of Ki-ras2 gene in human colon and lung carcinomas by two different point mutations", Nature, 304, pp.507~513 (1983)
21. Bos, J. L, "Amino-acid substitutions at codon 13 of the N-ras oncogene in human acute myeloid leukaemia", Nature, 315, pp.726~730 (1985)
22. Lièvre, A, "mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab", J. Clin. Oncol, 26, pp.374~379 (2008)
23. Amado, R. G, "Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer", J. Clin. Oncol, 26, pp.1626~1634 (2008)
24. Eberhard, D. A, "Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib", J. Clin. Oncol, 23, pp.5900~5909 (2005)
25. The Food and Drug Administration, "Drug-Diagnostic Co-Development Concept Paper", ~ (2005)
26. Holt, G. D, "The subcellular distribution of terminal N-acetylglucosamine moieties. Localization of a novel protein-saccharide linkage, O-linked GlcNAc", J. Biol. Chem, 061, pp.8049~8057 (1986)
27. Wang, Z, "Cross-talk between GlcNAcylation and phosphorylation: site-specific phosphorylation dynamics in response to globally elevated O-GlcNAc", Proc. Natl. Acad. Sci. U.S.A, 105, pp.13793~13798 (2008)
28. Maeda, Y, "Structural remodeling, trafficking and functions of glycosylphosphatidylinositol-anchored proteins", Prog. Lipid. Res, 50, pp.411~424 (2011)
29. Yu, R. K, "Structures, biosynthesis., functions of gangliosides-an overview", J. Oleo. Sci, 60, pp.537~544 (2011)
30. Helenius, A, "Intracellular functions of N-linked glycans", Science, 291, pp.2364~2369 (2001)
31. Roth,J, "Protein N-glycosylation along the secretory pathway: relationship to organelle topography and function, protein quality control, and cell interactions", Chem. Rev, 102, pp.285~303 (2002)
32. Ko, J. H, "Regulation of the GnT-V promoter by transcription factor Ets-1 in various cancer cell lines", J. Biol. Chem, 274, pp.22941~22948 (1999)
33. Dall'Olio, F, "Sialyltransferases in cancer", Glycoconj. J, 18, pp.841~850 (2001)
34. Cazet, A, "Consequences of the expression of sialylated antigens in breast cancer", Carbohydr. Res, 345, pp.1377~1383 (2010)
35. Itzkowitz, S. H, "Sialosyl-Tn. A novel mucin antigen associated with prognosis in colorectal cancer patients", Cancer, 66, pp.1960~1966 (1990)
36. Ma, X. C, "Expression of sialyl-Tn antigen is correlated with survival time of patients with gastric carcinomas", Eur. J. Cancer, 29A, pp.1820~1823 (1993)
37. Burchell, J. M, "O-linked glycosylation in the mammary gland: changes that occur during malignancy", J. Mammary Gland Biol. Neoplasia, 6, pp.355~364 (2001)
38. Hwang, S. Y, "Functional proteomics study reveals that N-acetylglucosaminyltransferase V reinforces the Invasive", Metastatic potential of colon cancer through aberrant glycosylation on tissue inhibitor of metalloproteinase-1, 2008, pp.7, 1~14[DOI]
39. Ben-David, T, "The involvement of the sLe-a selectin ligand in the extravasation of human colorectal carcinoma cells", Immunol. Lett, 116, pp.218~224 (2008)
40. Shirure, V. S, "Gangliosides expressed on breast cancer cells are E-selectin ligands. Biochem", Biophys. Res. Commun, 406, pp.423~429 (2011)
41. Chen, G, "Mature N-linked glycans facilitate UT-A1 urea transporter lipid raft compartmentalization", FASEB J (2011)
42. Hollenstein, K, "Structure and mechanism of ABC transporter proteins", Curr. Opin. Struct. Biol, 17, pp.412~418 (2007)
43. Beretta, G. L, "Increased levels and defective glycosylation of MRPs in ovarian carcinoma cells resistant to oxaliplatin", Biochem. Pharmacol, 79, pp.1108~1117 (2010)
44. Leffler, H, "Introduction to galectins", Glycoconj. J, 19, pp.433~440 (2004)
45. Fred Brewer, C, "Binding and cross-linking properties of galectins", Biochim. Biophys. Acta, 1572, pp.255~262 (2002)
46. Liu, F. T, "Galectins as modulators of tumour progression", Nat. Rev. Cancer, 5, pp.29~41 (2005)
47. Camby, I, "Galectin- 1: a small protein with major functions", Glycobiology, 16, pp.137R~157R (2006)
48. Garner, O. B, "Galectin-glycan lattices regulate cell-surface glycoprotein organization and signaling", Biochem. Soc. Trans, 36, pp.1472~1477 (2008)
49. Wu, A. M, "Lectins as tools in glycoconjugate research", Glycoconj. J, 26, pp.899~913 (2009)
50. Duverger, E, "Carbohydrate-lectin interactions assessed by surface plasmon resonance", Biochimie, 85, pp.167~179 (2003)
51. Ahn, H. J, "Generation of antibodies recognizing an aberrant glycoform of human tissue inhibitor of metalloproteinase-1 (TIMP-1) using decoy immunization and phage display", JOURNAL OF BIOTECHNOLOGY, 151(2), pp.225~230 (2011), ELSEVIER SCIENCE BV
52. Yoshida-Moriguchi, T, "O-mannosyl phosphorylation of alpha-dystroglycan is required for laminin binding", Science, 327, pp.88~92 (2010)

관련 논문AI추천